Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alpha Therapeutic’s Fluosol

Executive Summary

Intravascular perfluorochemical emulsion was listed by FDA as Fluosol-DA under the head "Biological Product Licenses Issued" in the agency's "January 1990-Prepared Report on NDA Approvals" ("The Pink Sheet" March 26, p. 13). The blood substitute is a drug product that received NDA approval on Dec. 26 ("The Pink Sheet" Jan. 8, p. 8). The DA was dropped from the tradename several years ago.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel